MDXG — MiMedx Group, Inc.

MDXG Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 2025 Revenue: $118 million, a 27% increase year-over-year.
• Wound Sales: $79 million, up 28% year-over-year.
• Surgical Sales: $39 million, up 25% year-over-year.
• Adjusted Gross Profit Margin: 86%.
• Adjusted EBITDA: $29 million, or 25% of net sales.
• Net Cash Position: $148 million, an increase of $24 million in Q4 and $63 million higher than the start of 2025.
• Full Year 2025 Results: $419 million in net sales (20% growth), GAAP net income of $49 million, and adjusted EBITDA of nearly $106 million (over 25% margin).

2. Strategic Updates and Business Highlights:

• The company is adapting to a new reimbursement framework in the Wound Care market, which is expected to stabilize over time.
• The Surgical business has shown strong growth, benefiting from investments in dedicated resources and product innovation.
• New product launches include AMNIOFIX Thyroid Shield and collaborations with Regen Labs for a PRP system.
• The company is committed to ongoing clinical research, with the EPIEFFECT trial nearing completion and plans for additional trials for new products.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to be between $340 million and $360 million, with Q1 anticipated to be the lowest quarter.
• Adjusted EBITDA Guidance: Expected to be in the mid- to high teens as a percentage of sales.
• Long-term outlook suggests a return to double-digit growth by 2027, with expectations to exceed $400 million in revenue.

4. Bad News, Challenges, or Points of Concern:

• The Wound Care market is facing disruptions due to a recalibration of Medicare reimbursement rates, leading to increased competition and price discounting.
• Some providers have ceased operations or reduced orders, contributing to market uncertainty.
• The implementation of new prior authorization requirements has slowed claims processing, creating additional operational challenges.
• There is a risk of overutilization and market resizing, complicating revenue projections.

5. Notable Q&A Insights:

• Management acknowledged anticipated disruptions in the Wound Care market due to new rules but remains confident in their competitive position.
• There is uncertainty regarding market share changes as the industry adjusts, with expectations for a gradual recovery in the Wound Care segment.
• The company plans to maintain flexibility in its sales force while focusing on supporting customers through the transition.
• Future product launches and clinical data generation are expected to enhance the company’s competitive edge in both Wound and Surgical markets.

Overall, MiMedx reported strong financial performance in Q4 2025 but faces significant challenges in the Wound Care market due to reimbursement changes. The company remains optimistic about its long-term growth prospects, particularly in its Surgical segment.